| Webinar | Status | Focus | Action |
|---|---|---|---|
| Webinar 4 | Live: May 12 | Women’s health & solid tumor oncology | Register now |
| Webinars 1-3 | On-demand | Obesity, rare disease, oncology | Watch recordings |
Join our expert analysts as they discuss how innovation is transforming outcomes for breast, ovarian, and bladder cancers.
Secure your seatHistorical research paradigms often excluded women, did not prioritize female-specific diseases or failed to account for sex-based differences contributing to inequitable health outcomes. As a result, individuals with ovarian cancer still experience late diagnosis and poor survival rates, a consequence of chronic underfunding.
For breast cancer, the unmet need has shifted to precision therapeutics for subtypes long considered untreatable. Meanwhile, women with bladder cancer have higher risks of recurrence and progression than men.
Join us to hear what it will take for these innovations to achieve durable clinical and commercial success.
A deep dive into the $150bn obesity market. Analysts discuss the metabolic revolution, next-generation GLP-1 therapies, innovation trends, and the role of oral vs. injectable treatments in this growing space.
Watch nowExplore how transformative therapies are reshaping management for high-burden chronic diseases and rare autoimmune conditions. This session covers expanding treatment paradigms and patient-impact considerations.
Watch nowLearn how Targeted protein degradation (TPD) is reshaping the therapeutic landscape for difficult-to-treat diseases. Our analysts explore pivotal trial data, competitive positioning, and long-term commercial impact.
Watch now